New service launched by YourGene Health: IONA Care+, offering non-invasive prenatal testing for expectant parents

In the realm of prenatal care, Yourgene Health, a company within the Novacyt group, has made a significant stride with the launch of IONA Care+. This comprehensive non-invasive prenatal screening service is now available in the UK, offering expectant parents and healthcare professionals a wide range of options for genetic conditions screening.

IONA Care+ is an extension of Yourgene's NIPT Service, first introduced in 2015. The service offers an extensive menu-based approach, allowing expectant parents to select screening tests for various genetic conditions. The NIPT Service menu includes Down's, Edwards', and Patau's syndromes, as well as other autosomal aneuploidies and monosomies, and sex chromosomal aneuploidies. With the addition of IONA Care+, the comprehensive menu now also includes clinically relevant microdeletion syndromes like DiGeorge Syndrome, Prader-Willi, Angelman, 1p36 deletion, Cri-du-Chat, and Wolf-Hirschhorn Syndrome.

Lyn Rees, CEO of Novacyt, stated that IONA Care+ is the most comprehensive clinical menu in their portfolio of screening tests offered to pregnant women by their Genomic Services' laboratories. The service utilizes Yourgene's IONA Nx NIPT Workflow for safe, fast, and accurate non-invasive prenatal testing (NIPT) results.

Expectant parents and healthcare professionals can choose from three different clinical options: IONA test, IONA Care, and IONA Care+, depending on their individual needs. The test is only available for singleton and monochorionic twin pregnancies. Screening results will be available from Yourgene Genomic Services' laboratories in Manchester, UK within 3-5 working days via their local midwife or private clinic.

Yourgene Health continues to enhance the non-invasive prenatal testing (NIPT) landscape 10 years later. The company is proud to be contributing to patient care and working with healthcare professionals to provide high-quality and safe screening for pregnant women.

It's important to note that this article does not provide new information about the impact of IONA Care+ on the UK's prenatal screening landscape or the number of women it could potentially benefit. Additionally, the article does not provide new information about the availability, pricing, or results delivery of IONA Care+, the eligibility criteria for the service, such as whether it is available for multiple pregnancies or not, or the performance or accuracy of IONA Care+ compared to other NIPT services.

In conclusion, Yourgene Health's launch of IONA Care+ marks a significant step forward in the field of non-invasive prenatal testing, offering expectant parents and healthcare professionals a more comprehensive range of options for genetic conditions screening.